Department of Oncology, Handan First Hospital, Handan City, China.
Medicine (Baltimore). 2024 May 31;103(22):e38301. doi: 10.1097/MD.0000000000038301.
Pulmonary mucoepidermoid carcinoma (PMEC) is a rare lung malignancy, especially in combination with ALK mutations, whose clinical presentation lacks specificity and for which there are no standardized treatment guidelines.
We report a case of a patient with PMEC-predominant primary lung cancer combined with an ALK mutation.
One patient was diagnosed with PMEC combined with ALK mutation.
After diagnosis by puncture pathology, the patient was treated with oral targeted drugs.
The patient's cough and fever were controlled, her diet improved significantly, and she gained 20 pounds in 6 months. During this period, the primary and metastatic foci in the lungs were significantly reduced on repeat chest CT.
PMEC combined with ALK mutation is an extremely rare primary lung cancer, and the diagnosis is mainly based on pathology, histology and immunohistochemistry. The application of molecularly targeted drugs to patients with mutations can significantly improve the prognosis of patients with PMEC, which is expected to be a new breakthrough in the treatment of PMEC.
肺黏液表皮样癌（PMEC）是一种罕见的肺部恶性肿瘤，特别是与 ALK 突变同时存在时，其临床表现缺乏特异性，且目前尚无标准化的治疗指南。
我们报告了一例以 PMEC 为主的原发性肺癌合并 ALK 突变的病例。
患者经穿刺病理诊断为 PMEC 合并 ALK 突变。
诊断明确后，患者口服靶向药物治疗。
患者咳嗽、发热得到控制，饮食明显改善，6 个月体重增加 20 磅。在此期间，重复胸部 CT 显示肺部的原发和转移灶明显缩小。
PMEC 合并 ALK 突变是一种极其罕见的原发性肺癌，主要依靠病理学、组织学和免疫组织化学进行诊断。对突变患者应用分子靶向药物可显著改善 PMEC 患者的预后，有望成为 PMEC 治疗的新突破。
